Literature DB >> 19809818

Investigation of occurrence of osteonecrosis of the femoral head after increasing corticosteroids in patients with recurring systemic lupus erythematosus.

Fumio Sekiya1, Ken Yamaji, Kwangseok Yang, Hiroshi Tsuda, Yoshinari Takasaki.   

Abstract

Osteonecrosis (ON) of the femoral head is known to occur commonly in cases with systemic lupus erythematosus (SLE) that received corticosteroid (CS) treatment. However, there have been no detailed reports about the onset of ON in cases with recurrence of SLE. Using MRI, we followed up 17 patients who experienced recurrence of SLE for at least 1 year at our hospital and in whom the CS dose was increased from a maintenance dose to middle to high dose to see if ON would occur. We then compared the group that developed ON and the group that did not with respect to patient characteristics, blood test results, changes in serum lipid levels, and CS dose. ON occurred in five subjects (29.4%), revealing that osteonecrosis occurs not only when CS are first administered but also in cases which the CS dose is increased for recurrence of SLE. Especially, serum cholesterol levels and its rate of increase soared rapidly soon after increasing the CS dose in the ON group as compared with the non-ON group (P < 0.05). This suggests that increased serum lipid levels might be a contributing factor to onset of ON. Moreover, SLE disease activity index 2000 (SLEDAI-2K) scores when the CS dose was increased were significantly (P < 0.05) higher in the ON group, suggesting that SLE disease activity itself is a risk factor for onset of ON.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19809818     DOI: 10.1007/s00296-009-1194-y

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  26 in total

1.  The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study.

Authors:  Kuo-An Lai; Wun-Jer Shen; Chyun-Yu Yang; Chung-Jung Shao; Jui-Ting Hsu; Ruey-Mo Lin
Journal:  J Bone Joint Surg Am       Date:  2005-10       Impact factor: 5.284

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

Review 3.  Pathophysiology and natural history of avascular necrosis of bone.

Authors:  Pierre Lafforgue
Journal:  Joint Bone Spine       Date:  2006-08-08       Impact factor: 4.929

4.  A high low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio as a potential risk factor for corticosteroid-induced osteonecrosis in rabbits.

Authors:  K Miyanishi; T Yamamoto; T Irisa; A Yamashita; S Jingushi; Y Noguchi; Y Iwamoto
Journal:  Rheumatology (Oxford)       Date:  2001-02       Impact factor: 7.580

5.  Risk factors for avascular bone necrosis in systemic lupus erythematosus.

Authors:  C C Mok; C S Lau; R W Wong
Journal:  Br J Rheumatol       Date:  1998-08

6.  Statin therapy decreases the risk of osteonecrosis in patients receiving steroids.

Authors:  J W Pritchett
Journal:  Clin Orthop Relat Res       Date:  2001-05       Impact factor: 4.176

Review 7.  Nontraumatic osteonecrosis of the femoral head: ten years later.

Authors:  Michael A Mont; Lynne C Jones; David S Hungerford
Journal:  J Bone Joint Surg Am       Date:  2006-05       Impact factor: 5.284

8.  Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study.

Authors:  S Agarwala; D Jain; V R Joshi; A Sule
Journal:  Rheumatology (Oxford)       Date:  2004-11-30       Impact factor: 7.580

9.  Avascular necrosis in systemic lupus erythematosus. Silent symmetric osteonecroses.

Authors:  J H Klippel; L H Gerber; L Pollak; J L Decker
Journal:  Am J Med       Date:  1979-07       Impact factor: 4.965

10.  Does alendronate prevent collapse in osteonecrosis of the femoral head?

Authors:  Takashi Nishii; Nobuhiko Sugano; Hidenobu Miki; Jun Hashimoto; Hideki Yoshikawa
Journal:  Clin Orthop Relat Res       Date:  2006-02       Impact factor: 4.176

View more
  11 in total

1.  Systemic lupus erythematosus patients with high disease activity are associated with accelerated incidence of osteonecrosis: a systematic review and meta-analysis.

Authors:  Kui Zhang; Yan Zheng; Junfeng Jia; Jin Ding; Zhenbiao Wu
Journal:  Clin Rheumatol       Date:  2017-09-25       Impact factor: 2.980

2.  Effect of blood biochemical factors on nontraumatic necrosis of the femoral head : Logistic regression analysis.

Authors:  Ying Zhang; Ruibo Sun; Leilei Zhang; Lizhi Feng; Youwen Liu
Journal:  Orthopade       Date:  2017-09       Impact factor: 1.087

3.  High triglyceride is a risk factor for silent osteonecrosis of the femoral head in systemic lupus erythematosus.

Authors:  Takeshi Kuroda; Naohito Tanabe; Ayako Wakamatsu; Chinatsu Takai; Hiroe Sato; Takeshi Nakatsue; Yoko Wada; Masaaki Nakano; Ichiei Narita
Journal:  Clin Rheumatol       Date:  2015-09-18       Impact factor: 2.980

4.  Taxol activates inducible nitric oxide synthase in rat astrocytes: the role of MAP kinases and NF-kappaB.

Authors:  I Cvetkovic; D Miljkovic; O Vuckovic; L Harhaji; Z Nikolic; V Trajkovic; M Mostarica Stojkovic
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

Review 5.  Corticosteroid-induced Osteonecrosis of the Femoral Head: Detection, Diagnosis, and Treatment in Earlier Stages.

Authors:  Li-Hua Liu; Qing-Yu Zhang; Wei Sun; Zi-Rong Li; Fu-Qiang Gao
Journal:  Chin Med J (Engl)       Date:  2017-11-05       Impact factor: 2.628

Review 6.  Glucocorticoid-induced osteonecrosis in systemic lupus erythematosus patients.

Authors:  Kaichi Kaneko; Hao Chen; Matthew Kaufman; Isaak Sverdlov; Emily M Stein; Kyung-Hyun Park-Min
Journal:  Clin Transl Med       Date:  2021-10

7.  Osteonecrosis in systemic lupus erythematosus: an early, frequent, and not always symptomatic complication.

Authors:  Paola Caramaschi; Domenico Biasi; Ilaria Dal Forno; Silvano Adami
Journal:  Autoimmune Dis       Date:  2012-08-05

8.  Prevalence of Nontraumatic Osteonecrosis of the Femoral Head and its Associated Risk Factors in the Chinese Population: Results from a Nationally Representative Survey.

Authors:  De-Wei Zhao; Mang Yu; Kai Hu; Wei Wang; Lei Yang; Ben-Jie Wang; Xiao-Hong Gao; Yong-Ming Guo; Yong-Qing Xu; Yu-Shan Wei; Si-Miao Tian; Fan Yang; Nan Wang; Shi-Bo Huang; Hui Xie; Xiao-Wei Wei; Hai-Shen Jiang; Yu-Qiang Zang; Jun Ai; Yuan-Liang Chen; Guang-Hua Lei; Yu-Jin Li; Geng Tian; Zong-Sheng Li; Yong Cao; Li Ma
Journal:  Chin Med J (Engl)       Date:  2015-11-05       Impact factor: 2.628

9.  Silent osteonecrosis of the femoral head following high-dose corticosteroids in patients with systemic rheumatic diseases.

Authors:  Nahid Kianmehr; Ali Bidari; Mani Mofidi; Nasim Bahar
Journal:  Med J Islam Repub Iran       Date:  2015-09-08

10.  Avascular necrosis less frequently found in systemic lupus erythematosus patients with the use of alternate day corticosteroid

Authors:  Ismail Doğan; Umut Kalyoncu; Levent Kiliç; Ali Akdoğan; Ömer Karadağ; Sedat Kiraz; Şule A Bilgen; Ihsan Ertenli
Journal:  Turk J Med Sci       Date:  2020-02-13       Impact factor: 0.973

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.